BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27742064)

  • 1. Present and future of personalized medicine in CLL.
    Montserrat E; Bauman T; Delgado J
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):100-110. PubMed ID: 27742064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
    Buccheri V; Barreto WG; Fogliatto LM; Capra M; Marchiani M; Rocha V
    Ann Hematol; 2018 Dec; 97(12):2269-2278. PubMed ID: 30315344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?
    Tam CS; Stilgenbauer S
    Leuk Lymphoma; 2015 Mar; 56(3):587-93. PubMed ID: 25641428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic data in prognostic models-what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia.
    Chin-Yee B; Sadikovic B; Chin-Yee IH
    Br J Haematol; 2020 Mar; 188(5):652-660. PubMed ID: 30836431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 dysfunction in CLL: Implications for prognosis and treatment.
    Te Raa GD; Kater AP
    Best Pract Res Clin Haematol; 2016 Mar; 29(1):90-99. PubMed ID: 27742075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
    Montserrat E; Dreger P
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S74-81. PubMed ID: 27521330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving risk-stratification of patients with chronic lymphocytic leukemia using multivariate patient similarity networks.
    Turcsanyi P; Kriegova E; Kudelka M; Radvansky M; Kruzova L; Urbanova R; Schneiderova P; Urbankova H; Papajik T
    Leuk Res; 2019 Apr; 79():60-68. PubMed ID: 30852300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of TP53 for CLL diagnostics.
    Catherwood MA; Gonzalez D; Donaldson D; Clifford R; Mills K; Thornton P
    J Clin Pathol; 2019 May; 72(5):343-346. PubMed ID: 30712002
    [No Abstract]   [Full Text] [Related]  

  • 9. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.
    Shindiapina P; Brown JR; Danilov AV
    Br J Haematol; 2014 Oct; 167(2):149-61. PubMed ID: 25040077
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Campo E; Cymbalista F; Ghia P; Jäger U; Pospisilova S; Rosenquist R; Schuh A; Stilgenbauer S
    Haematologica; 2018 Dec; 103(12):1956-1968. PubMed ID: 30442727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical implications of gene mutations in chronic lymphocytic leukaemia.
    Rossi D; Gaidano G
    Br J Cancer; 2016 Apr; 114(8):849-54. PubMed ID: 27031852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.
    Rigolin GM; Saccenti E; Bassi C; Lupini L; Quaglia FM; Cavallari M; Martinelli S; Formigaro L; Lista E; Bardi MA; Volta E; Tammiso E; Melandri A; Urso A; Cavazzini F; Negrini M; Cuneo A
    J Hematol Oncol; 2016 Sep; 9(1):88. PubMed ID: 27633522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
    Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
    Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
    Do C; Best OG; Thurgood L; Hotinski A; Apostolou S; Mulligan SP; Lower K; Kuss B
    Br J Haematol; 2021 May; 193(3):556-560. PubMed ID: 33851417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study.
    De Luca G; Cerruti G; Lastraioli S; Conte R; Ibatici A; Di Felice N; Morabito F; Monti P; Fronza G; Matis S; Colombo M; Fabris S; Ciarrocchi A; Neri A; Menichini P; Ferrarini M; Nozza P; Fais F; Cutrona G; Dono M
    Hematol Oncol; 2022 Dec; 40(5):962-975. PubMed ID: 35961859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the best frontline therapy for patients with CLL and 17p deletion?
    Badoux XC; Keating MJ; Wierda WG
    Curr Hematol Malig Rep; 2011 Mar; 6(1):36-46. PubMed ID: 21153774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.
    Knittel G; Rehkämper T; Korovkina D; Liedgens P; Fritz C; Torgovnick A; Al-Baldawi Y; Al-Maarri M; Cun Y; Fedorchenko O; Riabinska A; Beleggia F; Nguyen PH; Wunderlich FT; Ortmann M; Montesinos-Rongen M; Tausch E; Stilgenbauer S; P Frenzel L; Herling M; Herling C; Bahlo J; Hallek M; Peifer M; Buettner R; Persigehl T; Reinhardt HC
    Nat Commun; 2017 Jul; 8(1):153. PubMed ID: 28751718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 mutation and survival in chronic lymphocytic leukemia.
    Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
    J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia.
    Kuss BJ; Tam CS
    Intern Med J; 2017 Dec; 47 Suppl 6():5-10. PubMed ID: 29250930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequencing of chronic lymphocytic leukemia therapies.
    Barrientos JC
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):128-136. PubMed ID: 27913471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.